These two symptoms are inter-related as the Aβ1–42 peptide can slow down the clearance of synaptically released glutamate by inducing mislocalization of astrocytic GLT-1, the major GLT in the adult brain [40], a process which has been employed to model several aspects of AD [41]. The gene discussed is SLC1A2; the disease is Alzheimer disease.